Literature DB >> 2235818

Ursodeoxycholic acid therapy in chronic active hepatitis.

M C Bateson1.   

Abstract

A 41 year old woman developed chronic active hepatitis with prominent cholestasis. She was treated with prednisolone over 3 years with symptomatic benefit and improvement in serum biochemistry. However, various steroid-related side effects were encountered and steatorrhoea eventually occurred with very troublesome nocturnal diarrhoea. Therapy with ursodeoxycholic acid 750 mg daily was started. Serum alanine aminotransferase and gamma-glutamyl transferase normalized for the first time since her illness began. Steatorrhoea was abolished. There was good control of symptoms as prednisolone therapy was gradually reduced. However, when prednisolone was completely withdrawn there was a prompt biochemical deterioration. Addition of low-dose azathioprine has maintained normal blood tests over 24 months without return of the original symptoms. There are no side effects of ursodeoxycholic acid in subjects without gallstones and this agent may be effective treatment for cholestatic liver disease.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2235818      PMCID: PMC2426868          DOI: 10.1136/pgmj.66.779.781

Source DB:  PubMed          Journal:  Postgrad Med J        ISSN: 0032-5473            Impact factor:   2.401


  14 in total

1.  Ursodeoxycholic acid in primary biliary cirrhosis.

Authors:  M C Bateson; P E Ross; B L Diffey
Journal:  Lancet       Date:  1989-04-22       Impact factor: 79.321

2.  Maintenance of remission in autoimmune chronic active hepatitis with azathioprine after corticosteroid withdrawal.

Authors:  A J Stellon; J J Keating; P J Johnson; I G McFarlane; R Williams
Journal:  Hepatology       Date:  1988 Jul-Aug       Impact factor: 17.425

3.  Norethisterone jaundice in two sisters.

Authors:  B N Somayaji; A Paton; J H Price; A W Harris; T H Flewett
Journal:  Br Med J       Date:  1968-05-04

4.  Deterioration of primary biliary cirrhosis during treatment with ursodeoxycholic acid.

Authors:  W Vogel; H Kathrein; G Judmaier; H Braunsteiner
Journal:  Lancet       Date:  1988-05-21       Impact factor: 79.321

5.  Treatment of primary biliary cirrhosis and cholestatic disorders with ursodeoxycholic acid.

Authors:  U Leuschner; W Kurtz
Journal:  Lancet       Date:  1987-08-29       Impact factor: 79.321

Review 6.  Bile acids, liver injury, and liver disease.

Authors:  R H Palmer
Journal:  Arch Intern Med       Date:  1972-10

7.  Sustained remission after corticosteroid therapy of severe hepatitis B surface antigen-negative chronic active hepatitis.

Authors:  A J Czaja; S J Beaver; M T Shiels
Journal:  Gastroenterology       Date:  1987-01       Impact factor: 22.682

8.  Bile acid metabolism in cirrhotic liver tissue--altered synthesis and impaired hepatic secretion.

Authors:  Y Akashi; H Miyazaki; J Yanagisawa; F Nakayama
Journal:  Clin Chim Acta       Date:  1987-09-30       Impact factor: 3.786

9.  Cyclosporine treatment of autoimmune chronic active hepatitis.

Authors:  J S Hyams; M Ballow; A M Leichtner
Journal:  Gastroenterology       Date:  1987-10       Impact factor: 22.682

10.  Is ursodeoxycholic acid an effective treatment for primary biliary cirrhosis?

Authors:  R Poupon; Y Chrétien; R E Poupon; F Ballet; Y Calmus; F Darnis
Journal:  Lancet       Date:  1987-04-11       Impact factor: 79.321

View more
  1 in total

1.  Effect of ursodeoxycholic acid administration on bile duct proliferation and cholestasis in bile duct ligated rat.

Authors:  E E Frezza; G E Gerunda; M Plebani; A Galligioni; A Giacomini; D Neri; A M Faccioli; C Tiribelli
Journal:  Dig Dis Sci       Date:  1993-07       Impact factor: 3.199

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.